12 mars 2024
info:eu-repo/semantics/openAccess
vroby, « UK – NICE publishes draft guidance not recommending CSL’s haemophilia B gene therapy », ELSIBI, ID : 10.58079/w08b
The National Institute for Health and Care Excellence (NICE) has issued a draft Appraisal Consultation Document that does not recommend CSL Behring’s Hemgenix (etranacogene dezaparvovec) gene therapy for haemophilia B. The Draft guidance document can be found on the NICE website. More information on RIS.World and PMLive.